Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
American Journal of Clinical Dermatology|May 27, 2026
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label StudyJoel C Joyce, H Chih-Ho Hong, Dareen D Siri, et al.
Journal of the American Academy of Dermatology|December 27, 2022
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
BMJ Oncology|January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursAung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
American Journal of Clinical Dermatology|November 15, 2024
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III StudiesEric L Simpson, Matthias Augustin, Diamant Thaçi, et al.
American Journal of Clinical Dermatology|May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 StudiesLawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.
Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
Drug Design, Development and Therapy|April 8, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in AustraliaJason D Lickliter, Hui K Gan, Mark Voskoboynik, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|December 23, 2021
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Pageof 3